- Investors are gobbling up nano cap BG Medicine (BGMD +15.6%) today. Shares are up 16% on 6x normal volume.
- The current up trend began on December 12 after the company announced a 69% increase in Medicare reimbursement for its Gelectin-3 blood test.
- Since then, the firm announced positive results for the automated version of the test and met NASDAQ Capital Markets' listing requirements.
- Consensus revenue estimates for 2013 and 2014 are $4.1M and $6.2M, respectively.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs